Cantor Fitzgerald upgrades Genomic Health (Nasdaq: GHDX) from Hold to Buy and raises its price target from $27 to $34.
This article: 123 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE